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Phospho-tyrosine levels are increased in melanoma,
apparently consistent with reports of elevated protein
tyrosine kinase activity. Some protein tyrosine
kinases are encoded by oncogenes and have been
implicated in melanoma genesis. Decreased protein
tyrosine phosphatase activity may also increase
phospho-tyrosine. Protein tyrosine phosphatase
genes are candidate tumor suppressors and loss of
expression may contribute to melanoma genesis.
Here we survey protein tyrosine phosphatase expres-
sion in pigment cells. Protein tyrosine phosphatase
genes were cloned by reverse transcriptase polymer-
ase chain reaction using degenerate primers based
upon conserved sequences within the phosphatase
catalytic domain. Reaction products were cloned
and sequenced: 118 and 113 partial protein tyrosine
phosphatase products were isolated from normal
melanocytes and melanoma cells, respectively.
Northern blotting analysis was used to study expres-
sion of 15 protein tyrosine phosphatase genes.
Expression of PTP-k and PTP-p was absent or
downregulated in more than 20% of melanoma cell
lines and in some unmanipulated melanoma biop-
sies. These closely related enzymes are members of
the 2B receptor protein tyrosine phosphatase family
previously implicated in contact inhibition. Loss of
protein tyrosine phosphatase expression may con-
tribute to the abnormal tyrosine phosphorylation
seen in melanoma; these genes are candidate tumor
suppressors. Key words: melanocyte/metastasis/PTP-k/
PTP-p. J Invest Dermatol 117:1255±1260, 2001
C
urrently, there is no effective therapy for advanced
melanoma (McMasters et al, 1999). Many studies
have searched for qualitative differences in signal
transduction pathways between normal and malig-
nant cells in the hope that these might be exploited
for the development of novel strategies for treatment. Recently,
attention has focused on protein-tyrosyl phosphorylation, a key
component of mammalian cellular signaling pathways (Hunter,
1998). Protein tyrosine phosphatases and kinases (PTP and PTK)
mediate signaling for multiple processes, including growth,
survival, differentiation, migration, and adhesion (Van der Geer
et al, 1994; Byon et al, 1997). These enzymes catalyze the addition
(kinases) or removal (phosphatases) of phosphate on tyrosyl residues
in substrate proteins. Certain PTK family members are onco-
proteins and mediate tumorigenesis in common solid cancers
(Hunter, 1998). Melanoma cells contain increased phospho-
tyrosine residues compared to their normal cellular counterparts
(Halaban et al, 1992), apparently re¯ecting overexpression of PTK
(Halaban et al, 1992; de Wit et al, 1992). Although PTK have been
extensively studied in melanoma, PTP have received little
attention. Long suspected to include the products of tumor
suppressor genes (Sun and Tonks, 1994; Hunter, 1998), PTP
may play a role in melanoma genesis; increased phospho-tyrosine
levels in melanoma may result from a loss of PTP expression.
Increased PTK activity is believed critical for melanoma
initiation and progression (Albino and Fountain, 1993; Chin et al,
1998). This assumption is based upon two types of data. First,
overexpression of some PTK has resulted in melanomas in
experimental animals; this includes X-Mrk in Xiphophorus
(Wellbrock et al, 1998), and Ret (Iwamoto et al, 1991) and HGF
(Otsuka et al, 1998), a ligand for Met, in transgenic mice. Human
melanocytic cells do not express RET, however (Easty et al,
1995b), and the relationship of such models to human melanoma
remains uncertain. In addition, transgenic animal cells express very
high levels of PTK, which are not reported for any PTK in human
melanoma cells. Second, increased expression of multiple PTK
genes occurs in melanoma (Easty and Bennett, 2000). Increases are
reported to occur, however, for multiple PTK genes, each in a
subset of melanomas (Gutman et al, 1994; Quong et al, 1994).
Moreover, immunohistochemical studies of speci®c PTK in
melanoma biopsies have been disappointing; no single, common
change (equivalent to, say, ERB-B2 in breast cancer) has been
identi®ed (Easty and Bennett, 2000). Nonetheless, we ®nd
particular PTK are likely to contribute to melanoma progression:
EPH-A2 in growth (Easty et al, 1995a), focal adhesion kinase in
adhesion (Maung et al, 1999), and KDR in metastasis1 (reviewed by
Easty and Bennett, 2000). Taken together, these data imply a role
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1Nesbit et al (submitted for publication).
for tyrosine phosphorylation in melanoma genesis, although the
mechanism remains uncertain.
Tyrosine phosphatases comprise cytoplasmic and receptor-like
families; full sequences are available for more than 75 PTP, and the
receptors have been divided into six main families (Neel and
Tonks, 1997). Little is known concerning their expression or
function in melanocytes. Tyrosine phosphatases are characterized
by a conserved catalytic domain of about 240 amino acids
containing a unique signature motif: (I/V)HCXAGXXR(S/T)G
(where X indicates any amino acid); the cysteinyl residue represents
the position for formation of a thio intermediate as part of the
reaction mechanism (Stone and Dixon, 1994). In general PTP
attenuate signals generated by PTK; they inhibit cell growth and
transformation by PTK (Brown-Shimer et al, 1992; Zander et al,
1993). Importantly, total cellular PTP activity is 100±1000 times
that of PTK (Sun and Tonks, 1994). This ®gure is an overview; it
does not consider the activity or compartmentalization of indi-
vidual PTP. In this regard, structural motifs within the intracellular
PTP localize these gene products to speci®c cellular compartments
and this is likely to determine substrate range (Neel and Tonks,
1997). Small alterations in PTK expression may not be functionally
signi®cant in the presence of normal levels of PTP activity.
Furthermore, most studies of PTK expression in melanoma have
found only small (less than 6-fold) increases in expression, and these
often occur in advanced melanoma (Easty and Bennett, 2000). In
the absence of PTK mutations (which have never been reported in
human melanoma) a marked overexpression, perhaps of the order
seen in animal models, might be required for transformation.
In order to learn more about PTP expression, we used reverse
transcriptase polymerase chain reaction (RT-PCR) to isolate partial
cDNAs from normal and malignant melanocytes. The highly
degenerate oligonucleotide primers used were based upon con-
served sequences from within the consensus catalytic domain of
PTP. We ®nd that melanocytic cells express a complex mixture of
PTP genes. Northern blotting analysis was used to test 15 PTP
genes in normal melanocytes and cell lines established from de®ned
stages of melanoma progression. Two closely related genes, PTP-p
and PTP-k, members of one receptor PTP subfamily, were
commonly downregulated in some melanoma cell lines and
unmanipulated biopsies. Loss of PTP genes may provide an
explanation for the increased amount of phospho-tyrosine reported
in melanoma; such PTP genes are candidate melanoma suppressors.
MATERIALS AND METHODS
Melanoma specimens Tissue from malignant melanoma specimens
was obtained as previously described (Florenes et al, 1992); biopsies were
snap frozen in liquid nitrogen immediately following surgery.
Culture of melanocytes and melanoma cell lines Normal human
melanocytes (FM1000, FM2056, FM2067) were isolated from neonatal
foreskins as described previously (Hsu and Herlyn, 1998); one additional
sample of melanocytes was from Clonetics (BioWhittaker, San Diego,
CA). Melanocytes were maintained in melanocyte growth medium
(MGM-3) containing insulin, hydrocortisone, basic ®broblast growth
factor, and phorbol myristate acetate (Clonetics). The melanoma cell
lines used here and their original sources have been described previously
(Easty et al, 1993, 1995a, 1995b; Hsu and Herlyn, 1998). Cell lines
WM9, WM239A, WM164, WM852, WM983A, WM1158, 451LU,
DX3, A375M, and COLO832 were derived from metastases; WM35,
WM793, WM1341B, WM1650, and SBcl2 were from primary
melanomas. Lines P1N1 and P2N1 were derived from WM35, WM793,
and WM1431B. The three parental lines failed to form tumors, or were
poorly tumorigenic (WM793) in animals. When inoculated in the
presence of Matrigel, derivative cell lines were isolated after one (P1N1)
or two (P2N1) passages in mice. These derivatives appeared more
tumorigenic in animals than the parental lines and resembled cells
derived from more aggressive vertical growth phase melanomas
(Kobayashi et al, 1994). These cell lines were a gift from Prof. Robert
Kerbel (Toronto). One early melanoma cell line (SBcl2) was cultured in
MCDB 153 with 20% L-15 medium and supplemented with 2 Mm Ca,
2% fetal bovine serum (FBS), and 5 mg per ml insulin (Hsu and Herlyn,
1998). All melanoma cell lines were maintained in Dulbecco's modi®ed
Eagle's medium supplemented with 5% FBS and glutamine and
incubated with 10% CO2, except where stated otherwise.
CDNA synthesis Poly(A+)-enriched RNA was isolated from normal
melanocytes and a metastatic melanoma cell line (451LU) using a
Fastrack 2.0 kit from Invitrogen. We prepared ®rst strand cDNA using
5 mg of poly(A+)-enriched RNA and a Superscript II kit from Gibco
BRL as per the manufacturer's instructions.
Degenerate PCR Degenerate primers derived from sequences within
the highly conserved region of the catalytic domain were used for PCR
to amplify multiple members of the PTP gene family from normal
melanocytes and 451LU melanoma cells. For PCR, degenerate sense [F1
and F2; encoding amino acids FWXMXW (single letter amino acid
code; X, any amino acid)] and antisense [B1, B2, and B3; encoding
HCSAG(I/V)] primers were used (Norris et al, 1997). Primer
combinations F1 + B1, F2 + B2, and F1 + B3 were contained in a 50 ml
reaction with 1 ml of the 451LU or melanocyte cDNA. The reaction
mixture was subjected to the conditions previously described: 95°C for
4 min; then 95°C for 1 min, 37°C for 2 min, and 72°C for 3 min for
three cycles; next 95°C for 1 min, 42°C for 2 min, and 72°C for 3 min
for ®ve cycles; next 95°C for 1 min, 47°C for 2 min, and 72°C for
3 min for ®ve cycles; and ®nally 95°C for 1 min, 53°C for 2 min, and
72°C for 3 min for 27 cycles. The PCR yielded products of about
400 bp; these were subcloned into pGEM-T (Promega). In addition,
speci®c primers were designed for PTP-1B, PTP-SIGMA, PTP-DELTA,
PTP-ZETA, PTP-EPSILON, and PTP-b using a MacVector version 4.5
program. Puri®ed PCR products were used for northern and southern
blotting analysis (Easty et al, 1995a).
Subcloning of degenerate PCR products Approximately 25 ng of
the PCR product was ligated to 50 ng of pGEM-T vector (Promega)
using T4 DNA ligase; products were transformed into JM109 competent
cells, and colonies were selected on LB-ampicillin plates.
DNA Sequencing For each clone, miniprep DNA was prepared as
previously described (Easty et al, 1993), and PTP gene fragments in
pGEM-T were ampli®ed using M13For and M13Rev primers. Clones of
the expected size were sequenced using an ABI PRISM Dye Terminator
Cycle Sequencing Ready Reaction Kit and ABI PRISM 310 Genetic
Analyzer. The resulting sequences were compared to the database using
the NCBI Blast program.
Northern blotting analysis Poly(A+)-enriched RNA was prepared
from cell lines as previously described (Easty et al, 1993); 2.5 mg or 5 mg
was electrophoresed through a 1% agarose-formaldehyde gel and
transferred to nitrocellulose membranes. Total RNA was isolated from
melanoma biopsies as previously described (Florenes et al, 1992). Probes
were labeled by random hexanucleotide priming; prehybridization and
hybridization were all as before (Easty et al, 1995a). Products cloned
from RT-PCR were used as probes for northern blotting (Table I);
additional PCR products used as probes (PTP-BAS, PTP-LAR, PTP-
H1, PTP-MEG1, TCELL-PTP, and PTP-SIGMA) were from normal
human mammary epithelial cells.2 The PCR products used as probes
detected transcripts of the expected size(s); in addition, southern blotting
analysis found single bands consistent with speci®c hybridization by
probes. For some PTP probes multiple transcripts were detected. These
blots were repeated with speci®c PCR products corresponding to
regions that excluded the conserved catalytic region and the same
transcript sizes were found, consistent with gene-speci®c hybridization.
The integrity and loading of RNA from cell lines was determined by
probing with glyceraldehyde phosphate dehydrogenase (GAPDH) and/or
actin; for the unmanipulated melanoma biopsies, a speci®c 18S rRNA
oligonucleotide was used for quantitation as previously described
(Florenes et al, 1992). Laser densitometry was used to scan auto-
radiographs, and the mRNA index was calculated as previously described
(Easty et al, 1995b). We regarded a difference in expression as signi®cant
whenever there was a 3-fold or greater difference compared to normal
melanocytes for two or more of the cell lines tested (Easty et al, 1993).
Southern blotting analysis DNA was extracted from melanoma cell
lines and control DNA from lymphoblastoid cell lines. Blotting was as
previously described (Easty et al, 1995a). DNA (10 mg) was digested with
restriction enzymes, fractionated by agarose gel electrophoresis, and
transferred to nylon membranes. Probes for PTP-LAR, PTP-k, and
PTP-p were isolated by PCR and used for southern blotting analysis.
2Rafferty et al: Eur J Cancer (submitted for publication).
1256 MCARDLE ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Immunoblotting analysis Cells were washed in phosphate-buffered
saline and lyzed in RIPA buffer containing protease inhibitors; biopsies
were processed for electrophoresis as previously described (Easty et al,
1995a). The protein concentration of each sample was determined using
the BCA protein assay (Pierce, Rockford, IL). Samples were electro-
phoresed through 6% gels and transferred to nitrocellulose membranes
(Pall Corporation, MI). Immunoblotting was carried out using an af®nity
puri®ed goat polyclonal speci®c antibody for PTP-k (Santa Cruz
Biotechnology, Santa Cruz, CA), diluted 1:1000. Binding of the primary
antibody was detected using a Vectorstain ABC kit; membranes were
incubated with biotin conjugated antigoat antibody (diluted 1:2000),
followed by peroxidase conjugated avidin according to the
manufacturer's instructions (Vector, Burlingame, CA). Speci®c antibody
binding was determined using an enhanced chemoluminescence
detection kit (ECL, Amersham, Arlington Heights, IL), as per the
manufacturer's instructions.
RESULTS
PCR cloning of PTP from melanocytes and melanoma
cells We used highly degenerate primers directed to the
conserved catalytic domain for RT-PCR to isolate PTP
expressed in melanocytes and a melanoma cell line (451LU). The
ampli®ed products (approximately 350±400 bp) were cloned and
sequenced. For each cell type approximately 200 clones were
isolated, and 118 (from melanocytes) and 113 (from 451LU) had
sequence identity, or homology to known PTP when compared to
EMBL and GenBank databases. In total, nine different (®ve
receptor and four cytoplasmic) partial PTP genes were identi®ed
(Table I). Seven PTP were isolated from 451LU cells. Out of
these, PTP-g was not found in normal melanocytes. On the other
hand, eight distinct PTP were present in melanocytes, and two of
these (PTP-p and PTP-D1) were not isolated from 451LU cells.
The incidence of PTP-PEST clones was high in both normal
melanocytes and malignant melanoma cells and may re¯ect
abundant expression of this gene, seen by northern blotting
analysis. The numbers of clones isolated corresponding to each
speci®c PTP gene are likely to be determined by the primer
sequences used for PCR and the absolute amount of mRNA
present for each PTP gene. The incidence is nonquantitative, but
provides an indication of PTP gene expression in each cell type. In
particular, as only low numbers of clones were isolated for PTP-p
and PTP-D1 from the normal melanocytes, we could not discount
the possibility that melanoma cell line 451LU might also express
both of these genes.
Northern blotting analysis of PTP Northern blotting analysis
was used to investigate the expression of PTP isolated by RT-
PCR. A panel of melanocytes and melanoma cell lines was tested to
determine expression of 15 PTP genes, and representatives of these
blots are shown in Fig 1(a, b); Table II contains data from laser
densitometry. Only the PTP-MEG1 probe failed to detect a
message; signals for all of the remaining genes were found in some
cultured melanocytic cells. The expression of PTP differed between
normal melanocytes and melanoma cell lines. Two cytoplasmic
(PTP-1B and PTP-H1) and one receptor (PTP-g) sequences were





n % n %
Receptors
m k 4 3.4 5 5.5
p 2 1.7 0 0
a a 5 4.2 2 1.8
b Dep-1 4 3.4 3 2.7
g g 0 0 15 10.9
Cytoplasmic
PEST Pest 84 71.2 73 65.5
1B 1B 15 12.7 14 12.7
BAND 4.1 Meg 2 1.7 1 0.9
D1 2 1.7 0 0
aThe observed incidences are given as absolute numbers (n) and as a percentage
of all PTP clones derived from that cell type. It should be emphasized, however,
that this gives little information on the original relative abundance of transcripts as
other factors contribute to the frequency of ampli®cation by PCR.
Figure 1. Northern blot analysis of poly(A+) RNA enriched from
normal melanocytes and melanoma cell lines (5 mg per lane). The
normal melanocyte RNA is under-loaded. (a) Hybridization was to
MEG2, PTP-1B, PTP-k, DEP-1, and b-ACTIN probes; durations of
exposure were 7, 3, 2, 7, and 1 d, respectively. (b) Hybridization was to
PTP-BAS, PTP-g, PTP-p, PTP-D1, and b-ACTIN probes; durations of
exposure were 2, 2, 12, 2, and 1 d, respectively.
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more highly expressed in some melanomas (Fig 1, and data not
shown). This is consistent with the absence of PTP-g from clones
isolated from normal melanocytes by RT-PCR (Table I). On the
other hand, several PTP genes (PTP-k, PTP-p, PTP-BAS, and
PTP-D1) showed loss or downregulated expression in two or more
malignant melanoma cell lines. The normal melanocyte samples in
Fig 1 are under-loaded; however, this does not affect the
conclusion that PTP expression was decreased in some melanoma
cell lines. Whereas a signal for PTP-k was clearly visible in (the
under-loaded) normal melanocytes, WM9 contained only trace
amounts of PTP-k, and no transcript was detected in WM239A
cells (Fig 1a). Similarly, PTP-p was found in normal melanocytes
(Fig 1b) but was not detected in WM793 and WM239A cells.
PTP-D1 was expressed in four out of six melanoma cell lines in
quantities greater than trace amounts; in one cell line (WM164),
expression of PTP-D1 was increased compared to melanocytes.
In an initial blot, expression of PTP-k was increased in two
melanoma cell lines (Fig 1a); however, when PTP gene expression
was tested on a larger panel of cell lines PTP-k and PTP-p were
consistently downregulated in multiple samples (Fig 2a, b). These
two closely related members of a small family of receptors,
previously implicated in the mediation of contact inhibition (Fuchs
et al, 1996), were chosen for further study. PTP-k was detected in
three of three normal melanocyte cultures. Only 11 of 14 (78%)
melanoma cell lines contained more than trace amounts of PTP-k
message, however (Table III); with extended autoradiography a
signal was detected for WM1341B (Fig 2a). Matrigel selection did
not signi®cantly affect PTP-k expression and derived lines (P1N1,
P1N2) generally maintained similar expression patterns to the
parental cell line. In Table III each group of parental melanoma
and derived subclones was scored as a single observation.
Interestingly, PTP-k was detected in three of four cell lines
derived from early primary melanomas suggesting that loss of
expression may occur early in progression in some melanomas
(Table III). PTP-p was found in two of two normal melanocytes
and in SBCl2 cells derived from an early melanoma, but was not
detected in three of ten (30%) melanoma cell lines (Fig 2b); in
addition, expression was downregulated in most (®ve of nine)
of the melanoma cell lines tested. In some cases both PTP-k and
PTP-p were downregulated in the same cell line (including
WM239A).
Unmanipulated melanoma biopsies were tested by northern
blotting analysis; representative blots are shown in Fig 3. PTP-BAS
was detected in RNA derived from six of nine metastatic
melanoma biopsies. In the case of PTP-k, 13 of 25 samples were
strongly positive; a further four biopsies contained small amounts of
message, and in eight of 25 biopsies no signal was detected. PTP-p
was easily detected in only one of nine melanoma biopsies; trace
amounts were found in three further samples, and six of nine
biopsies did not contain PTP-p message. Interestingly, the
expression of PTP-p and PTP-k overlapped to some degree;
both genes were lost in some melanoma biopsies and four of six of
the biopsies positive for PTP-k also contained PTP-p. Expression
Figure 2. Northern blot analysis of poly(A+)-enriched RNA from
normal melanocytes and melanoma cell lines (5 mg per lane). (a)
Hybridization was to PTP-k and GAPDH probes; durations of exposure
were 1 d and 1 h, respectively. (b) Hybridization was to PTP-p and
GAPDH probes; durations of exposure were 4 d and 1 h, respectively.
Table II. Quantitation of PTP mRNA expression in human
melanocyte and melanoma cell lines
Phosphatase
MEG2 1B k DEP-1
Experiment 1b
Normal 2 100 100 100 100
Wm793 104 505 363 7
WM9 7 219 31 Trc.
WM239a 104 265 Trc. Trc.
Wm1158 141 792 395 76
Wm164 122 986 173 65
BAS g D1 PI
Experiment 2b
Normal 2 100 Trc. 100 100
WM793 53 100 8 Trc.
Wm164 163 1876 224 ND
Wm1158 189 887 887 ND
WM9 31 145 Trc. 0
WM239a Trc. Trc. Trc. Trc.
Cellsa p a
Experiment 3b









PTP-k was detected in three cell lines derived from metastatic melanoma
(DX3, COLO832, A375P) and four cell lines (WM1650, WM793,
WM35, and WM1341B) derived from early melanomas; WM1341B cells
(and sublines derived from WM1341B) contained trace amounts of
PTP-k.
aAll cell lines are metastatic melanomas except the Radial Growth Phase (non-
metastatic) cell line WM793 and the melanocytes (Normal).
bFor experiment 1, levels of expression were normalized to Normal 2 (de®ned as
100). For experiment 2 levels of expression were normalized to Normal 2; except
for PTP-g where expression was compared with WM793. Experiment 3 was nor-
malized to Normal 1. Trc. indicates trace amounts of RNA are present that could
not be quantitated based upon laser densitometry; 0 indicates that no signal was de-
tectable. Expression was regarded as signi®cantly different when there was 3-fold
variation compared to the reference cell line for two or more melanoma cell lines.
ND (not done); for the PTP-p blot the high background compromised densitome-
try and these values are not included here.
cPTP mRNA expression was quantitated by laser densitometry of autoradio-
graphs. Relative expression levels were normalized to GAPDH mRNA expression
and to one cell line for each probe as described (Materials and Methods). Data are
from four independent experiments as shown.
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did not appear to correlate with histopathology of the primary
melanoma or clinical data (survival time) of the patient.
Southern blotting analysis of PTP To test for alterations in
PTP genes, control lymphoblastoid cells were compared with
melanoma cell lines by southern blotting analysis; we found no
evidence for deletions or gross rearrangements of PTP-k or PTP-p.
Immunoblotting analysis A speci®c polyclonal antibody was
used to determine expression of PTP-k in melanocytic cells; an
antibody for PTP-p was not available. Cell lysates from pigmented
cells and positive controls gave immunoreaction signals that were
barely above background. These did not yield acceptable data for
quantitation and are not included here. Hence the antikappa
antibody did not provide consistent results. To the author's
knowledge this is the only antikappa antibody currently
commercially available.
DISCUSSION
Melanomas and the cell lines derived from them contain increased
amounts of phospho-tyrosine compared to their normal cellular
counterparts. This appears to re¯ect overexpression of PTK,
enzymes encoded by a multigene family, which includes trans-
forming oncogenes. On the other hand, loss of PTP expression may
also contribute to increased phospho-tyrosine. Our hypothesis was
that PTP, downregulated or lost during melanoma progression,
would include the products of tumor suppressor genes. In order to
learn more about PTP expression, we used RT-PCR to isolate
partial cDNAs from normal and malignant melanocytes.
Speci®c PTP sequences detected in pigment cells We have
identi®ed 15 different PTP, and signi®cantly extended the
repertoire of known PTP in melanocytic cells. A number of
phosphatases were identi®ed here only once and others present
were probably not found by our PCR analysis. For example, PTP-
DELTA and PTP-ZETA expression have been detected in
melanoma cells using other methods (Halaban et al, 1992;
Goldmann et al, 2000). Some omissions are expected, however,
as the products of PCR are in¯uenced by stochastic events, target
sequence, and concentration. The role of PTP in human melanoma
has received little attention; to date there has only been one
previous study. Halaban et al (1992) found seven PTP present in
both melanoma cell lines and normal melanocytes; PTP-DELTA
was not detected in normal melanocytes, but was present in two
out of four melanoma cell lines.
We ®nd a complex pattern of expression for 14 PTP genes;
speci®c increases and decreases in PTP expression occurred in
malignant cells. PTP-1B, PTP-H1, PTP-DEP, and PTP-g were
overexpressed in some melanoma cell lines. Increased expression of
PTP genes has previously been found in other malignant cells,
including breast cancer cell lines (Zhai et al, 1993). The reason for
increased PTP expression in cancer cells is unclear, but activation of
oncogenes (such as ERB-B2 in breast cancer) may result in
phosphorylation of multiple substrates, including those involved in
growth and morphologic transformation, but also housekeeping
proteins involved in other essential metabolic processes. Hence,
PTK overexpression may be deleterious and this effect may be
circumvented by increases in the expression of speci®c PTP.
It would also be of interest to study PTP in melanoma at the
protein level. Due to the lack of presently available suitable
antibodies speci®c for PTP, however, this is not currently possible.
This present situation perhaps re¯ects the paucity of previous
studies concerning PTP in comparison to PTK, and suggests that
PTP have been neglected and will be an important area for further
research.
PTP-k and PTP-p Two PTP genes were selected for further
study: PTP-k and PTP-p. Expression of these genes was decreased
or lost compared to normal melanocytes in more than 20% of
melanoma cell lines. The relevance of results from cultured cells to
the potential expression and function in unmanipulated tumors was
unclear, however. We therefore studied gene expression of PTP-k
and PTP-p in unmanipulated biopsies and again found this was
reduced below levels required for detection in multiple melanoma
samples.
Several studies have shown that receptor PTP are involved in
cell±cell adhesion (Neel and Tonks, 1997). PTP-k and PTP-p
belong to the small 2B subgroup of receptor PTP that includes
PTP-MU. These receptors consist of an extracellular segment
containing a MAM domain, an Ig domain, four ®bronectin-type III
repeats, a transmembrane segment, and two tandem intracellular
PTP domains (Neel and Tonks, 1997). The role of the 2B family of
receptor PTP is uncertain and experiments are currently under way
to determine the effect of forced expression of PTP-k in melanoma
cells that do not express this protein. As PTP-k and PTP-MU are
localized to adherens junctions, mediate homotypic adhesion
in vitro, and regulate phosphorylation of cadherin±catenin com-
plexes (Brady-Kalnay et al, 1998), they may contribute to cell±cell
communication (Fuchs et al, 1996).
PTP-k seems to be a particularly good candidate as a tumor
suppressor gene; it is upregulated by transforming growth factor b
(a negative regulator of cell growth) and has been implicated in
contact inhibition (Yang et al, 1996). In addition, PTP-k has been
mapped to 6q22.2-3 (Zhang et al, 1998), a common site for
chromosome rearrangements in melanoma (Albino and Fountain,
1993). The close sequence homology of these downregulated genes
suggests that the proteins they encode will have similar cellular
functions. In this regard, it is not clear whether downregulation of
both gene products (PTP-k and PTP-p) is required for melanoma
genesis; interestingly, this did occur in some of the melanoma cell
lines and biopsies tested. We found loss of or decreased expression
of PTP-k in some cell lines derived from early melanomas; in
Table III. Comparison of PTP-k and PTP-p mRNA









k 3/3a 3/4 9/11 17/25
p 2/2 3/3 5/7 4/9
aExpression of selected mRNAs is shown as number of cell lines containing
mRNA in quantities greater than trace amounts divided by the number of samples
tested. Uncultured metastases were biopsy specimens (see Materials and Methods).
Expression was quantitated by laser densitometry of autoradiographs; for cultured
cells relative expression was normalized to that in melanocytes. Figure 3. Northern blot analysis of total RNA from human
metastatic melanoma biopsies (5 mg per lane). L, S, Lu, samples
derived from lymph node, subcutaneous and lung metastases,
respectively; ND, site of metastasis not determined. Hybridization was to
PTP-BAS, PTP-k, and PTP-p probes; an 18S rRNA speci®c
oligonucleotide was used for quantitation. Durations of exposure were 5,
8, 12, and 1 d, respectively.
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contrast, overexpression of PTK (including EPH-A2; Easty et al,
1995a; Bittner et al, 2000) has generally been reported in advanced
melanomas (Easty and Bennett, 2000). One possible explanation
may be that loss of PTP(s) occurs as an early event, and that
subsequent small changes in PTK(s) expression are late events in
melanoma progression. This sort of interaction (between PTK and
PTP) has been hypothesized to occur in other human tumors. In
chronic myeloid leukemia cells, recent data suggest that, in addition
to generation of Bcr-abl, loss of a PTP is necessary for transform-
ation (LaMontagne et al, 1998). Moreover, aggressive human breast
cancer cell lines (rapid growing in athymic mice) contained high
expression of ERB-B2 and lower levels of PTP compared to slower
growing tumors (Zhai et al, 1993).
In summary, we report abnormal PTP expression in well-
characterized melanoma cell lines previously shown to overexpress
speci®c PTK (Easty and Bennett, 2000). As the activity of PTP is
signi®cantly greater than that of PTK (Neel and Tonks, 1997),
increases in PTK expression appear more likely to be functionally
signi®cant when combined with downregulation of PTP activity.
Taken together, these changes offer an explanation for the
abnormal phospho- tyrosine previously reported in melanoma.
Upregulation of PTK expression has been implicated in melanoma
genesis; it seems likely that decreased PTP activity will also impact
upon the control of this process.
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